Metastatic Type II Papillary Renal Cell Carcinoma With Recurrent Complete Responses to Sunitinib: A Case Report With a Literature Review

Bayan H Al Ashour; Faisal Azam; Fahad Ibnshamsah; Fahad Alrowais; Ayed Al-Garni; Humaid O Al-Shamsi; Nedal Bukhari

doi:10.7759/cureus.25541

Metastatic Type II Papillary Renal Cell Carcinoma With Recurrent Complete Responses to Sunitinib: A Case Report With a Literature Review

Cureus. 2022 May 31;14(5):e25541. doi: 10.7759/cureus.25541. eCollection 2022 May.

Authors

Bayan H Al Ashour¹, Faisal Azam², Fahad Ibnshamsah^{2

3}, Fahad Alrowais⁴, Ayed Al-Garni⁵, Humaid O Al-Shamsi^{6

7

8}, Nedal Bukhari^{2

3}

Affiliations

¹ Collage of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU.
² Department of Medical Oncology, King Fahad Specialist Hospital, Dammam, SAU.
³ Department of Internal Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU.
⁴ Department of Radiation Oncology, King Fahad Specialist Hospital, Dammam, SAU.
⁵ Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, SAU.
⁶ Depatment of Oncology, Emirates Oncology Society, Dubai, ARE.
⁷ Department of Oncology, Burjeel Cancer Institute, Abu-Dhabi, ARE.
⁸ College of Medicine, University of Sharjah, Sharjah, ARE.

Abstract

Papillary renal cell carcinoma (PRCC) is a less common subtype of kidney cancer and is typically more resistant to systemic treatments. This report describes a patient with metastatic type II PRCC who experienced two complete responses (CR) to the tyrosine kinase inhibitor (TKI) sunitinib. The patient remains on sunitinib with durable control of the disease. To the best of our knowledge, this is the first case of metastatic type II PRCC with CR to sunitinib.

Keywords: complete response; papillary; renal cell carcinoma; sunitinib; tyrosine kinase inhibitors.

Publication types

Case Reports